The Global Fund Board has approved two of the nine Round 9 proposals whose original rejection had been appealed by the applicants. The newly approved proposals are an HIV proposal from Pakistan that will cost $11.9 million and a TB proposal from Ukraine that will cost $34.6 million (costs are for the first two years). The approvals are subject to a number of requests for clarification being successfully responded to in a timely manner.
The Global Fund Board has approved funding for 31 Round 9 proposals that had been recommended by the Technical Review Panel (TRP), but for which funding was not formally approved at the Board's in-person meeting in November 2009.
In December 2009, the Global Fund Board approved nine proposals in Wave 7 of the rolling continuation channel (RCC) funding stream, representing costs of up to $451 million over three years. Of the nine proposals, three were for HIV, four for TB and two for malaria. All approvals are conditional on the applicant responding satisfactorily to clarifications requested by the Technical Review Panel (TRP).
The Global Fund recently released a wide-ranging Frequently Asked Questions (FAQ) document on how to implement decisions made by the Global Fund Board in November 2009 concerning cost-cutting measures and the new grant architecture. The document is entitled "Grant Signing Frequently Asked Questions," though in fact it covers many issues beyond those related to grant signing.
The Global Fund is planning several initiatives to address the need for better planning and coordination of technical assistance (TA). This information is included in the "Management Response to the Five-Year Evaluation," a document presented at the twentieth meeting of the Global Fund Board in Addis Ababa in last month.
In Issue 111, GFO reported briefly on a Global Fund Board decision in November 2009 to further modify its Quality Assurance Policy for Pharmaceutical Products. This article provides some background information and further details of the decision.
The Board had previously approved a revised Quality Assurance Policy at its meeting in November 2008. That revised policy came into effect on 1 July 2009.
The Global Fund Board has decided to implement a new funding architecture in order to simplify processes for grant implementers. The centrepiece is the concept of a "single stream of funding" per PR per disease.
Global Fund Board Approves Proposals for Phase 1 of the "AffordableMedicines Facility - Malaria" (AMFm) Funding Stream
At its recent meeting in Addis Ababa, the Global Fund Board approved 10 proposals under Phase 1 of a small innovative new funding programme called the "Affordable Medicines Facility - Malaria" (AMFm), which is designed to provide support for interventions promoting and facilitating the use of artemisinin combination therapies (ACT).
On 9-11 November 2009, the Global Fund Board held its twentieth board meeting, in Addis Ababa, Ethiopia. GFO was present, with observer status.
GFO's next issue, targeted for publication in the next few days, will provide information on the other key decisions made at the November 9-11 Board meeting.